Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06949826 · ClinicalTrials.gov registry record · Phase 4
Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery
A Phase 4 study of Opioid Use Disorder and Pain, Postoperative, sponsored by Jenna-Leigh Wilson.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06949826 is a Phase 4 study of Opioid Use Disorder and Pain, Postoperative that is actively recruiting participants, run by Jenna-Leigh Wilson. The registered enrollment target is 100 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06949826, a Phase 4 study of Opioid Use Disorder and Pain, Postoperative, is actively recruiting participants, sponsored by Jenna-Leigh Wilson.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery. Buprenorphine is an opioid with unique properties that may offer a way to reduce the number of patients that become addicted to opioids after surgery. Buprenorphine has good analgesic (painkilling) effects. It is also thought to be less addictive and cause less of a high than full-agonist opioids, like oxycodone and hydrocodone. This project's goal is to determine if transdermal buprenorphine can safely and effectively control pain after ankle fracture surgery. This study will be a pilot study, which sets the stage for future studies that investigate whether buprenorphine can reduce the rate that patients become addicted to opioids after surgery. This study's multidisciplinary team will divide patients into two groups. Participants in one group will be treated with a 7-day transdermal buprenorphine patch (where the buprenorphine is slowly absorbed through the skin over 7 days). Participants in the other group will be treated with a placebo patch. A placebo has no drug in it, it just looks like the buprenorphine patch. Aside from the buprenorphine patch or placebo patch, both groups' pain management plans will be the same as if they were not in the study. Over the first week after surgery, the investigators will measure the amount of full-agonist opioids (for example, oxycodone or hydrocodone) that participants consume, participants' pain scores, the frequency of side effects related to opioids, and the number of calls and patient portal messages to the clinic for uncontrolled pain. The investigators will also assess whether participants are continuing to use opioids 3 months after surgery for pain related to their ankle fracture.
Conditions Studied
Interventions
- DRUG Placebo Patch
- DRUG Buprenorphine Transdermal System
Study Locations (1)
Missouri
- Washington University in St. Louis/Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2027-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06949826
The ClinicalTrials.gov registry entry for NCT06949826 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Jenna-Leigh Wilson, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo Patch is the first listed.
NCT06949826 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT06949826 about?
NCT06949826 is a clinical study titled "Buprenorphine as a Post-operative Analgesic in Opioid-Naive Patients After Ankle Fracture Surgery". Addictive full-agonist opioids, like oxycodone and hydrocodone, are often used to treat pain after surgery. However, these full-agonist opioids can be very addictive. After ankle fracture surgery, about 1 in 5 patients that did not take opioids before surgery become addicted to opioids after surgery...
What is the current status of trial NCT06949826?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2025-04-21. Estimated completion is 2027-06.
What conditions does trial NCT06949826 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Pain, Postoperative, Opioid Dependence, Opioid Analgesia, Ankle Fracture Surgery.
What interventions are being tested in trial NCT06949826?
The interventions under investigation include: Placebo Patch (DRUG), Buprenorphine Transdermal System (DRUG).
Who is sponsoring clinical trial NCT06949826?
This trial is sponsored by Jenna-Leigh Wilson, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06949826 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Integrated e-Health (Electronic Health) for HIV and Substance Use Disorders in Justice Involved Women
RECRUITING · Phase 4
-
A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
RECRUITING · Phase 4
-
Assessing Optimal XRB Initiation Points in Jail
RECRUITING · Phase 4
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
RECRUITING · Phase 4
-
Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.
RECRUITING · Phase 4
-
Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.